The next petition, PE1863, which was lodged by Michael Campbell, calls on the Scottish Parliament to urge the Scottish Government to provide mandatory annual cancer blood tests to people from the age of 55. When the petition was previously considered on 1 September, we agreed that we would write to various stakeholders to ask for their view on the petition. Those stakeholders included the United Kingdom National Screening Committee, which is the independent scientific advisory body that advises ministers on matters of population screening, including any proposal to consider a single blood test to detect cancers. The UK National Screening Committee’s submission notes that it
“has not looked at the evidence to screen for cancers using a single blood test.”
However, its call for topics to consider runs from September to December each year.
Cancer Research UK notes that there are currently no blood tests that can
“reliably detect the early signs of cancer in people without symptoms”,
and it suggests that a “lot more research” would be required before such a test could be used in cancer screening. Cancer Research UK also provides information about a large screening trial on a single blood test, which it believes will be “crucial” in answering whether such a test can find cancer, whether it can do so at an earlier stage and whether it can avoid causing undue levels of harm. Cancer Research UK concludes:
“Regrettably we cannot endorse this petition, but we hope that it will not be too much longer before a general cancer blood test suitable for use in cancer screening becomes available.”
It looks as though the petitioner’s aims might be feasible at a later date, but we cannot find any advisory body that wishes to pursue the matter at the moment. On the basis that there is no such test at this time, I am minded to suggest to colleagues that we close the petition under rule 15.7. In doing so, we could say to the petitioner that there is an expectation and a hope that such a test might be possible in the not-too-distant future. We could also write to those in the national health service who are running the Galleri trial, to see what information they have for us to consider.